Boehringer Ingelheim Company Profile

✉ Email this page to a colleague

What is the competitive landscape for BOEHRINGER INGELHEIM, and what generic alternatives to BOEHRINGER INGELHEIM drugs are available?

BOEHRINGER INGELHEIM has forty-eight approved drugs.

There are sixty-nine US patents protecting BOEHRINGER INGELHEIM drugs.

There are one thousand seven hundred and eighty-two patent family members on BOEHRINGER INGELHEIM drugs in sixty-three countries and two hundred and seventeen supplementary protection certificates in nineteen countries.

Summary for Boehringer Ingelheim

International Patents:	1782
US Patents:	69
Tradenames:	37
Ingredients:	29
NDAs:	48
Patent Litigation for Boehringer Ingelheim:	See patent lawsuits for Boehringer Ingelheim
PTAB Cases with Boehringer Ingelheim as petitioner:	See PTAB cases with Boehringer Ingelheim as petitioner

Drugs and US Patents for Boehringer Ingelheim

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-001	Jan 30, 2012	AB	RX	Yes	No	8,673,927*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No	10,022,379	⤷ Try a Trial	Y			⤷ Try a Trial
Boehringer Ingelheim	SYNJARDY	empagliflozin; metformin hydrochloride	TABLET;ORAL	206111-004	Aug 26, 2015		RX	Yes	Yes	11,090,323*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-002	Dec 9, 2016		RX	Yes	No	7,579,449*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	AB	RX	Yes	Yes	7,407,955*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-003	Dec 30, 1985		DISCN	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	PELLETS;ORAL	214358-001	Jun 21, 2021		RX	Yes	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Boehringer Ingelheim

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-003	Jul 1, 1997	6,194,445	⤷ Try a Trial
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015	6,303,661	⤷ Try a Trial
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020	8,178,541	⤷ Try a Trial
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004	7,070,800*PED	⤷ Try a Trial
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-006	Feb 12, 1998	4,843,086	⤷ Try a Trial
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015	7,459,428	⤷ Try a Trial
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016	7,459,428	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	eq. to 110 mg base	➤ Subscribe	2015-12-15
➤ Subscribe	Oral Suspension	7.5 mg/5 mL	➤ Subscribe	2009-12-17
➤ Subscribe	Extended-releaseTablets	2.5 mg/1000 mg 5 mg/1000 mg	➤ Subscribe	2018-03-28
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2015-05-04
➤ Subscribe	Extended-release Tablets	2.25 mg and 3.75 mg	➤ Subscribe	2011-07-26
➤ Subscribe	Extended-release Tablets	400 mg	➤ Subscribe	2013-06-21
➤ Subscribe	Tablets	10 mg/5 mg and 25 mg/5 mg	➤ Subscribe	2018-08-01
➤ Subscribe	Tablets	2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg	➤ Subscribe	2015-05-04
➤ Subscribe	Tablets	80 mg/12.5 mg and 40 mg/12.5 mg	➤ Subscribe	2008-12-31
➤ Subscribe	Extended-release Capsules	25 mg and 200 mg	➤ Subscribe	2007-02-01
➤ Subscribe	Tablets	0.125 mg, 0.5 mg, 1 mg and 1.5 mg	➤ Subscribe	2005-06-24
➤ Subscribe	Capsules	eq. to 75 mg base and 150 mg base	➤ Subscribe	2014-10-20
➤ Subscribe	Tablets	0.75 mg	➤ Subscribe	2008-07-31
➤ Subscribe	Inhalation Powder Capsules	18 mcg	➤ Subscribe	2018-05-11
➤ Subscribe	Tablets	5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg	➤ Subscribe	2018-08-01
➤ Subscribe	Extended-release Tablets	0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg	➤ Subscribe	2010-06-01
➤ Subscribe	Extended-release Tablets	5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg	➤ Subscribe	2018-08-01
➤ Subscribe	Tablets	20 mg, 30 mg and 40 mg	➤ Subscribe	2017-07-12
➤ Subscribe	Tablets	10 mg and 25 mg	➤ Subscribe	2018-08-01
➤ Subscribe	Tablets	20 mg, 40 mg and 80 mg	➤ Subscribe	2006-12-26
➤ Subscribe	Tablets	80 mg/25 mg	➤ Subscribe	2009-02-27
➤ Subscribe	Capsules	100 mg and 150 mg	➤ Subscribe	2018-10-15
➤ Subscribe	Tablets	0.25 mg	➤ Subscribe	2005-05-27

International Patents for Boehringer Ingelheim Drugs

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Hong Kong	1134076	⤷ Try a Trial
European Patent Office	1536792	⤷ Try a Trial
Japan	4594317	⤷ Try a Trial
Spain	2412754	⤷ Try a Trial
Lithuania	2482806	⤷ Try a Trial
Mexico	2015013948	⤷ Try a Trial
Morocco	33936	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Boehringer Ingelheim Drugs

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1830843	300747	Netherlands	⤷ Try a Trial	PRODUCT NAME: NINTEDANIB, OF EEN TAUTOMEER, DE MENGSELS DAARVAN OF EEN ZOUT DAARVAN; IN HET BIJZONDER NINTEDANIBESILAAT; REGISTRATION NO/DATE: EU/1/14/979 20150115
2187879	LUC00017	Luxembourg	⤷ Try a Trial	PRODUCT NAME: GLYXAMBI- EMPAGLIFLOZINE/LINAGLIPTINE; AUTHORISATION NUMBER AND DATE: EU/1/16/1146 20161115
0186087	SPC/GB98/017	United Kingdom	⤷ Try a Trial	PRODUCT NAME: PRAMIPEXOLE, OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT, IN PARTICULAR PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE; REGISTERED: UK EU/1/97/050/001 19971014; UK EU/1/97/050/002 19971014; UK EU/1/97/050/003 19971014; UK EU/1/97/050/004 19971014; UK EU/1/97/050/005 19971014; UK EU/1/97/050/006 19971014; UK EU/1/97/050/007 19971014; UK EU/1/97/050/008 19971014; UK EU/1/97/050/009 19971014; UK EU/1/97/050/010 19971014
1532149	91889	Luxembourg	⤷ Try a Trial	91889, EXPIRES: 20260824
1485094	CA 2012 00054	Denmark	⤷ Try a Trial	PRODUCT NAME: DABIGATRAN-ETEXILAT OG SALTENE DERAF; SAERLIGT DABIGATRAN-ETEXILAT-MESYLAT; REG. NO/DATE: EU/1/08/442/009-014 20080318
1830843	C201530043	Spain	⤷ Try a Trial
1532149	C 2012 003	Romania	⤷ Try a Trial	PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-IL)-7-BUT-2-INIL-3-METIL-1-(4-METILCHINAZOLIN-2-ILMETIL)3,7-DIHIDROPURIN-2,6-DIONA, ENANTIOMERII SI SARURILE LOR IN SPECIAL LINAGLIPTIN - LINAGLIPTIN, ENANTIOMERIISI SARURILE ACCEPTABILE FARMACEUTIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/707/001 - RO EU/1/11/707/011; DATE OF NATIONAL AUTHORISATION: 20110824; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/707/001 - EU/1/11/707/011; DATE OF FIRST AUTHORISATION IN EEA: 20110824
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Boehringer Ingelheim

Summary for Boehringer Ingelheim

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs

Similar Applicant Names

Make Better Decisions: Try a trial or see plans & pricing